Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect

Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect

Eli Lilly is licensing rights to a Phase 1-ready antibody that startup Alchemab developed for amyotrophic lateral sclerosis and other neurodegenerative disorders. Lilly’s pipeline has ALS drug candidates from previous deals with QurAlis and Verge Genomics. The post Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect appeared first on MedCity News.

Lilly forges a $415m ALS alliance with UK biotech Alchemab

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients

Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly - Pharmafile

Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, its leading programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. While Alchemab will take the programme through phase 1 clinical trials, Lily will lead further development and commercialisation. The transaction is worth a total […] The post Alchemab Therapeutic…

Prilenia partners with Ferrer to advance pridopidine for ALS

Prilenia Therapeutics has entered a collaboration and license agreement with Ferrer to codevelop and commercialize pridopidine, its therapy candidate for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), in Europe and other select markets. The partnership comes as pridopidine nears an expected regulatory decision in the European Union, where it’s being reviewed by the European Medicines Agency for use in Huntington’s disease. …

Eli Lilly signs $415m deal for Alchemab’s ALS therapy   - Pharmaceutical Technology

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Lilly partners with Alchemab for ALS candidate

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415m deal, expanding its neuroscience pipeline with a novel, AI-discovered candidate.